Abstract:6030 Background: Neoadjuvant is a promising chemotherapy modality for recurrent nasopharyngeal carcinoma (NPC). However, there is still controversy for locally advanced NPC. We study the survival results of locally advanced NPC treated with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NACT) retrospectively, and to explore the potential beneficiaries. Methods: 147 stage III-IVa+b NPC treated with IMRT were included and divided into two groups. NACT group (76) received 2-3 cycles of neoadjuvant chemotherapy with TP or TPF, and then 2-3 cycles of platinum-based chemoradiotherapy (CCRT). CCRT group (71) received 3 cycles of platinum-based chemoradiotherapy. TNM stage, age and whole blood count before treatment were all collected. The stratified analysis was used for distinguishing the potential beneficiaries. Results: median follow-up time was 30 months. For all patients, the 3-year LRRFS, DMFS and OS in NACT and CCRT were 94.5%, 96.8%; 85.8%, 82.8% and 81.6%, 83.4% respectively ( p> 0.05). For stage III patients, the 3-year LRRFS, DMFS and OS were 95.2%, 97.3%; 91.4%, 84.6% and 86.3%, 82.1% respectively ( p= 0.38, p= 0.15, p= 0.58). Though there was no statistical significance, DMFS in NACT was better than it in CCRT. However, for stage IV, the survival rate had no significant difference. The incidence of grade 3-4 bone marrow suppression was higher in NACT ( p= 0.007), and the other toxicities were similar. Univariate analysis showed the percentages of neutrophil and neutrophil-to-lymphocyte ratio (NLR) were significantly correlated with OS ( p= 0.031, p= 0.049). N and clinical stage were the adverse prognostic factors for OS ( p= 0.025, p= 0.007) and DMFS ( p= 0.018, p= 0.001). Clinical stage was the prognostic factors for OS and DMFS in multivariate analyses ( p= 0.019, p= 0.01). Conclusions: NACT had a comparable survival results and tolerable toxicity with CCRT for locally advanced NPC. Stage III might be the potential beneficiaries from NACT, especially for DMFS. Percentages of neutrophil and NLR might be the new adverse prognostic factor for OS. Clinical stage was still the prognostic factor for OS and DMFS.

Clinical curative effect on neoadjuvant chemotherapy in locally advanced oral cavity cancers

Neoadjuvant Chemotherapy Versus Surgery Alone For Locally Advanced Gastric Cancer: A Retrospective Comparative Study

Definitive Surgery after Neoadjuvant Chemotherapy for Locally Advanced Oral Cavity Cancers: Experience from a Tertiary Care Center

Therapeutic effect of neoadjuvant chemotherapy on local advanced cervical carcinoma

Preliminary Outcome of the Survival Rate and Possible Prognostic Factors for Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy.

Effect of neoadjuvant therapy on serum transforming growth factor-, squamous cell carcinoma associated antigen, and prognosis in patients with locally advanced esophageal cancer

Effect of neoadjuvant therapy on serum transforming growth factor-β, squamous cell carcinoma associated antigen, and prognosis in patients with locally advanced esophageal cancer

Premilinary Survival Results and Potential Beneficiaries for Locally Advanced Nasopharyngeal Carcinoma Treated with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy.

A Preliminary Study of Efficacy of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer

Effect of Neoadjuvant Chemotherapy in Treatment of Locally Advanced Breast Cancer with Cytologically Proven Axillary Node Metastases

Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study

The Impact of Neoadjuvant Chemotherapy and Adjuvant Chemotherapy on NSCLC Supported by Evidence-based Medicine

Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study

Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Reduces Surgical Risks and Lymph-Vascular Space Involvement

Impact of Neoadjuvant Chemotherapy on the Postoperative Pathology of Locally Advanced Cervical Squamous Cell Carcinomas: 1:1 Propensity Score Matching Analysis.

Effect of preoperative oral S-1 combined with regional intra-arterial chemotherapy on malig-nant molecule expression in locally advanced unresectabIe gastric cancer tissue

Acquired Treatment Response from Neoadjuvant Chemotherapy Predicts a Favorable Prognosis for Local Advanced Cervical Cancer

Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer.

Analysis of surgical complexity and short-term prognostic indicators in NSCLC patients: neoadjuvant targeted therapy versus neoadjuvant chemoimmunotherapy

Curative Effect Analysis of Locally Advanced Non-smallCell Lung Cancer with Surgical Treatment

Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.